News

Inventiva Showcases Positive Phase 2 Results for Lanifibranor

Inventiva Showcases Positive Phase 2 Results for Lanifibranor

Inventiva's Promising Data on Lanifibranor and Empagliflozin

Inventiva, a clinical-stage biopharmaceutical company, is set to present the results from the final analysis of its Phase 2 study that evaluates the combination of lanifibranor with empagliflozin. This combination targets patients suffering from Metabolic Dysfunction-Associated Steatohepatitis (MASH) as well as Type 2 Diabetes (T2D). The findings will be shared during the late-breaker poster session at a prestigious event.

Study Outcomes and Efficacy Improvements

The results will be presented during a significant event, with expectations for attendees to gain insights about the study's successful outcomes. One of the most notable findings from this analysis is that the combination therapy significantly lowered Hemoglobin A1c (HbA1c) levels in patients compared to placebo. Specifically, 50% of patients saw their HbA1c levels drop below 6.5% after 24 weeks of treatment, demonstrating a strong efficacy signal for both treatment groups.

Numerical Achievements of the Study

In detail, the figures reflect that 58% of patients receiving lanifibranor alone experienced at least a 1% reduction in HbA1c, while 80% of those taking the combination therapy witnessed similar improvements. This is particularly striking when compared to the 0% noted in the placebo group, highlighting the therapy's effectiveness in managing diabetes related to MASH.

Comprehensive Health Benefits Observed

Not only did the treatment lead to better diabetes management, but it also showed improvements in liver function tests and various cardiometabolic health markers. Patients benefitted from enhancements in insulin sensitivity and reductions in inflammation markers. Moreover, the study noted no weight gain among patients on the combination therapy, contrasting with some mild increases seen in the lanifibranor-only group.

Clinical and Metabolic Insights

Imagery assessments indicated a significant reduction in hepatic steatosis, a key factor in MASH progression. Patients showcased a -49% reduction in fat content with lanifibranor alone and -41% when combined with empagliflozin. The results lend evidence to the potential for lanifibranor to address the underlying biology of MASH effectively.

Expert Opinions on Study Findings

Dr. Michael Cooreman, Chief Medical Officer of Inventiva, expressed enthusiasm about sharing these findings at the upcoming conference. He noted the importance of confirming lanifibranor's monotherapy benefits while supporting the treatment regime for patients through combination therapy. These insights are vital for healthcare practitioners and researchers focusing on this disease area.

Furthermore, Dr. Nezam Afdhal, a leading expert in gastroenterology, remarked on the significance of addressing insulin resistance through targeted treatments like lanifibranor and empagliflozin. He indicated that the results should alleviate common concerns around weight gain associated with certain diabetes therapies, empowering practitioners to choose effective combinations for managing T2D in MASH patients.

About Inventiva and its Future Prospects

Inventiva specializes in developing innovative therapies for metabolic diseases like MASH/NASH. Their lead candidate, lanifibranor, is currently undergoing pivotal Phase 3 trials. This concentrated pipeline showcases the company’s commitment to addressing significant unmet medical needs.

With a robust team of around 90 experts and proprietary access to a vast library of pharmacological compounds, Inventiva remains at the forefront of the biopharmaceutical industry. The team's strength lies in their vast experience with nuclear receptors and transcription factors.

Frequently Asked Questions

What is the primary focus of Inventiva?

Inventiva primarily focuses on developing oral small molecule therapies for metabolic diseases, particularly MASH/NASH.

What were the findings regarding weight management in the study?

The combination therapy of lanifibranor and empagliflozin did not result in weight gain, contrasting with the slight increase observed in those taking lanifibranor alone.

How effective was the therapy in managing diabetes?

50% of patients achieved HbA1c levels below 6.5% after 24 weeks, demonstrating significant efficacy in diabetes management.

Who are the key experts involved in this research?

Dr. Michael Cooreman and Dr. Nezam Afdhal are notable figures that have spoken positively about the study's outcomes and its implications for treating MASH and T2D.

What is the next step for Inventiva’s therapy development?

Inventiva is enhancing its clinical pipeline, focusing on lanifibranor through ongoing pivotal Phase 3 studies aiming for regulatory approval.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 44

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 0

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 326

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 419

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 0

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 231

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 37

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 269

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Willis Towers Watson's P/E Ratio Dynamics

Updated Category News Views 190

Current Stock Overview In today's market, Willis Towers Watson Inc. stock is priced at $325.59, reflecting a slight increase of 0.02%. Over the past month, the stock has risen by 5.11% and has shown a notable yearly increase of 17.73%. Such performance has led to optimism among long-term shareholders, although many are considering the price-to-earnings (P/E) ratio as a...

Continue Reading
Sterling Infrastructure to Engage Investors at Key Conferences

Updated Category News Views 79

Sterling Infrastructure to Engage Investors at Key Conferences Sterling Infrastructure, Inc. (NASDAQ: STRL) is making strides in connecting with investors by participating in several upcoming investor conferences. These events present a fantastic opportunity for the company's management to share insights and updates regarding their ongoing projects and strategic...

Continue Reading
Rivian's $5 Billion Factory Plans and Market Dynamics in EV

Updated Category News Views 224

Exciting Developments in the EV Industry The electric vehicle (EV) space has witnessed some thrilling changes recently. Major companies like Rivian, Tesla, and BYD are at the forefront of this industry evolution. This article will recap some standout events that have kept the tech world buzzing. Rivian's Ambitious Factory Plans Construction Begins on a $5 Billion Facility...

Continue Reading
Berry Global Group Secures $800 Million in Senior Notes

Updated Category News Views 273

Berry Global Group's Strategic $800 Million Notes Issuance Berry Global Group, Inc. (NYSE: BERY) has taken a significant step in bolstering its financial structure with the announcement of the issuance of $800 million in senior secured notes due in 2031. The notes, which carry an attractive interest rate of 7.250% per annum, reflect the company's ambition and strategic...

Continue Reading
AdaptHealth Corp. Welcomes Russell Schuster as CCO for Growth

Updated Category News Views 108

Russell Schuster Joins AdaptHealth as Chief Commercial Officer AdaptHealth Corp. (NASDAQ: AHCO), a prominent provider of patient-centered healthcare-at-home solutions, has made a significant addition to its leadership team by appointing Russell Schuster as Chief Commercial Officer. His role is effective immediately and brings a wealth of expertise aimed at enhancing the...

Continue Reading